Imidazopyridine derivatives as A 2B adenosine receptor...

Details Imidazopyridine derivatives as A 2B adenosine receptor... Imidazopyridine derivatives as A 2B adenosine receptor...

2006-10-05

2010-12-21

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S303000, C514S253040, C514S255050, C514S256000, C546S018000, C544S362000, C544S405000, C544S333000, C544S127000

Reexamination Certificate

active

07855202

ABSTRACT:
The present disclosure relates to imidazopyridine derivatives of formula (I):The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2Badenosine receptor.

REFERENCES:
patent: 5763448 (1998-06-01), Carling et al.
patent: 5849753 (1998-12-01), Yoo et al.
patent: 5916905 (1999-06-01), Weier et al.
patent: 6750232 (2004-06-01), Harada et al.
patent: 6841549 (2005-01-01), Asano et al.
patent: 7396836 (2008-07-01), Harada et al.
patent: 2003/0229106 (2003-12-01), Kalla et al.
patent: 2004/0006082 (2004-01-01), Harada et al.
patent: 2004/0176399 (2004-09-01), Elzein et al.
patent: 2005/0004149 (2005-01-01), Harada et al.
patent: 2007/0265273 (2007-11-01), Vidal Juan et al.
patent: 2009/0023763 (2009-01-01), Vidal Juan et al.
patent: 2009/0030023 (2009-01-01), Harada et al.
patent: 2009/0042891 (2009-02-01), Vidal Juan et al.
patent: 2 463 284 (2003-05-01), None
patent: 1 221 444 (2002-07-01), None
patent: 1 283 056 (2003-02-01), None
patent: 1 308 441 (2003-05-01), None
patent: 1 439 175 (2004-07-01), None
patent: WO 97/33883 (1997-09-01), None
patent: WO 98/24782 (1998-06-01), None
patent: WO 99/32448 (1999-07-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 00/73307 (2000-12-01), None
patent: WO 01/02400 (2001-01-01), None
patent: WO 01/16134 (2001-03-01), None
patent: WO 01/60350 (2001-08-01), None
patent: WO 01/62233 (2001-08-01), None
patent: WO 02/14282 (2002-02-01), None
patent: WO 02/20495 (2002-03-01), None
patent: WO 02/22608 (2002-03-01), None
patent: WO 02/24893 (2002-03-01), None
patent: WO 02/42298 (2002-05-01), None
patent: WO 03/002566 (2003-01-01), None
patent: WO 03/035639 (2003-05-01), None
patent: WO 03/042214 (2003-05-01), None
patent: WO 03/057689 (2003-07-01), None
patent: WO 03/063800 (2003-08-01), None
patent: WO 03/068773 (2003-08-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/105666 (2003-12-01), None
patent: WO 2004/022540 (2004-03-01), None
patent: WO 2004/030635 (2004-04-01), None
patent: WO 2004/076450 (2004-09-01), None
patent: WO 2004/106337 (2004-12-01), None
patent: WO 2005/021548 (2005-03-01), None
patent: WO 2005/033085 (2005-04-01), None
patent: WO 2005/040151 (2005-05-01), None
patent: WO 2005/040155 (2005-05-01), None
patent: WO 2005/042534 (2005-05-01), None
patent: WO 2005/070926 (2005-08-01), None
patent: WO 2005/100353 (2005-10-01), None
patent: WO 2007/017096 (2007-02-01), None
patent: WO 2008/080461 (2008-07-01), None
Nadeem et al., American journal of physiology. Lung cellular and molecular physiology, (Jun. 2007) vol. 292, No. 6, pp. L1335-L1344.).
International Search Report mailed Sep. 1, 2007, for International Application No. PCT/EP2006/009620 (WO 2007/039297 A1).
Feoktistov, I. et al. “Adenosine A2BReceptors,”Pharmacological Reviews, 49(4): 381-402 (1997).
Holgate, S.T. “The identification of the adenosine A2Breceptor as a novel therapeutic target in asthma,”British Journal of Pharmacology, 145: 1009-1015 (2005).
U.S. Appl. No. 12/521,133, Aug. 12, 2009, Bosch et al.
U.S. Appl. No. 10/574,101, Mar. 8, 2007, Vidal Juan et al.
U.S. Appl. No. 11/578,386, Jun. 2, 2008, Vidal Juan et al.
U.S. Appl. No. 11/997,048, Mar. 6, 2008, Vidal Juan et al.
Al-Masoudi, N.A.L. et al. “Nucleosides LIII* Syntheses and Reactions of 6,7-Dipyridyllumazine and 2′-Deoxylumazine N-1 Nucleosides,” Pteridines, 4(3): 119-125 (1993).
Barnes, PJ, “Theophylline New Perspectives for an Old Drug,” American Journal of Respiratory and Critical Care Medicine, 167: 813-818 (2003).
Bondavalli, Francesco et al., “3-5-diphenyl-1H-pyrazole derivatives IX. 2-substituted 4-phenyl-5-(3,5-diphenyl-1H- pyrazol-1-yl) pyrimidines with platelet antiaggregating and other activities,” Il Farmaco, 47(2):171-190 (1992).
Cacciari, Barbara et al., “A2B adenosine receptor antagonists: recent developments,” Mini-Reviews in Medicinal Chemistry, 5:1053-1060 (2005).
CAPLUS English Abstract of journal article by Tarkhov, L.I. et al. Accession No. 2005:630607 (2005).
CAPLUS English Abstract of journal article by Tarkhov, L.I. et al. CAS Registry No. 875932-62-0 (2009).
CAPLUS English-language abstract for Ried, Walter et al. “Synthesis of new cyclophanes from pyrazinedicarbonitriles” (1989).
Derwent WPI, Abstract of WO 02/14282 A1, dated Feb. 21, 2002, “New 2-aminopyridine compounds are adenosine receptor antagonists for treating e.g. constipation, irritable bowel syndrome, diabetes, asthma and Parkinson's disease.”
Fischer, Gerhard W., et al., “Tetrazole compounds. 8[1]. Synthesis of tetrazolylpyrimidines from tetrazolyl-substituted enamino ketones,” J. Heterocyclic Chem., 30:1517-1519 (1993).
Fozard, JR et al. “Adenosine receptor ligands as potential therapeutics in asthma,” Current Opinion in Investigational Drugs, 3(1): 69-77 (2002).
Gao et al., Expert Opin. Emerging Drugs (2008) 12(3) 479-492.
Haskö, György, et al., “Adenosine receptors: therapeutic aspects for inflammatory and immune diseases,” Nature Reviews, 7:759-770 (2008).
Haskö, György, et al., “Adenosine: an endogenous regulator of innate immunity,” Trends in Immunology, 25(1):33-51 (2004).
International Search Report dated Jul. 21, 2005, for Application No. PCT/EP2005/003818.
International Search Report for PCT/EP2004/010664 (WO 2004/040155) dated Dec. 27, 2004.
International Search Report mailed Nov. 22, 2006, for International Application No. PCT/EP2006/007318 (WO 2007/017096 A1).
International Search Report mailed Mar. 3, 2008, for International Application No. PCT/EP2007/010162 (WO 2008/080461 A1).
Jacobson, Kenneth A., et al, “Adenosine receptors as therapeutic targets,” Nature Reviews, 5:247-264 (2006).
King, FD “Bioisosteres, Conformational Restriction, and Pro-drugs—Case History: An Example of a Conformational Restriction Approach,” Principles and Practice, Chapter 14: 208-225 (1994).
Lappas, CM et al. “Adenosine A2Aagonists in development for the treatment of inflammation,” Expert Opinion Investig. Drugs, 14(7): 797-806 (2005).
Notice of Allowance dated Aug. 28, 2009 for U.S. Appl. No. 10/574,101.
Notice of Allowance dated Mar. 3, 2010 for U.S. Appl. No. 11/997,048.
Office Action dated Jun. 19, 2009 for U.S. Appl. No. 11/997,048.
Office Action dated Mar. 30, 2009 for U.S. Appl. No. 10/574,101.
Office Action dated Oct. 6, 2008 for U.S. Appl. No. 10/574,101.
Office Action dated Oct. 26, 2009 for U.S. Appl. No. 11/997,048.
Palanki, Moorthy S.S., et al., “Structure-activity relationship studies of ethyl 2-[(3-methy1-2,5,dioxo(3-pyrrolinyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An inhibitor of AP-1 and KF-kB Mediated Gene Expression,” Bioorganic & Medicinal Chemistry Letters, 12:2573-2577 (2002).
Peart, Jason N., et al., “Adenosinergic cardioprotection: multiple receptors, multiple pathways,” Pharmacology & Therapeutics, 114:208-221 (2007).
Polosa, R., “Adenosine-receptor subtypes: their relevance to adenosine-medicated responses in asthma and chronic obstructive pulmonary disease,” Eur Respir J., 20:488-496 (2002).
Ried, W. et al. “Synthese neuer Cyclophane aus Pyrazindicabonitrilen,” Chemiker-Zeitung, 112(12): 385 (1988).
Restriction Requirement for co-pending U.S. Appl. No. 11/997,048 dated May 1, 2009.
Rusinov, L.V. et al. “Synthesis and Antiviral Activity of 2-Amino-3-Ethoxycarbonylpyrazine Derivatives,” Pharmaceutical Chemistry Journal, 39(12): 630-635 (2005).
Schurreit, T. “4-Hydroxy-2H-[1]benzopyran-2on als Baustein zur Synthese von Bisbenzopyranopyridinen,” Archiv der Pharmazie (1987) 320:500-506.
Sitkovsky et al. British Journal of Pharmacology (2008) 153:5457-5464.
Tarkhov, LI et al. “Photoluminescence of some indolylpyrazines,” Materialovedenie, (4): 16-22 (2005) Not in English but with English abstract (Note

Affiliated with

Also associated with

Rating

Imidazopyridine derivatives as A 2B adenosine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazopyridine derivatives as A 2B adenosine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyridine derivatives as A 2B adenosine receptor... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4202050